Stevard, LLC Crispr Therapeutics Ag Transaction History

Stevard, LLC

$115 Million
Q2 2024

A detailed history of Stevard, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Stevard, LLC holds 5,011 shares of CRSP stock, worth $252,353. This represents 0.23% of its overall portfolio holdings.

Number of Shares

5,011

Previous 5,407 7.32%

Holding current value

$252,353

Previous $368,000 26.63%

% of portfolio

0.23%

Previous 0.33%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$51.17 - $68.18 $20,263 - $26,999	-396 Reduced 7.32%	5,011 $270,000
Q1 2024 May 13, 2024	BUY	$60.67 - $89.12 $7,341 - $10,783	121 Added 2.29%	5,407 $368,000
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $204,145 - $381,543	5,286 New	5,286 $330,000
Q2 2023 Aug 11, 2023	SELL	$43.47 - $67.77 $59,206 - $92,302	-1,362 Reduced 23.82%	4,356 $244,000
Q1 2022 May 13, 2022	SELL	$53.19 - $79.24 $51,541 - $76,783	-969 Reduced 14.49%	5,718 $359,000
Q4 2021 Feb 10, 2022	SELL	$70.09 - $111.29 $94,621 - $150,241	-1,350 Reduced 16.8%	6,687 $507,000
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $10,358 - $14,724	94 Added 1.18%	8,037 $900,000
Q2 2021 Aug 13, 2021	BUY	$100.84 - $161.89 $4,235 - $6,799	42 Added 0.53%	7,943 $1.29 Million
Q1 2021 Aug 13, 2021	SELL	$110.72 - $210.04 $66,874 - $126,864	-604 Reduced 7.1%	7,901 $963,000
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $258,369 - $561,784	-3,243 Reduced 27.6%	8,505 $1.3 Million
Q3 2020 Nov 12, 2020	BUY	$78.5 - $100.64 $182,120 - $233,484	2,320 Added 24.61%	11,748 $983,000
Q2 2020 Aug 11, 2020	BUY	$38.5 - $76.05 $362,978 - $716,999	9,428 New	9,428 $693,000

Others Institutions Holding CRSP

# of Institutions

504

Shares Held

57.1M

Call Options Held

1.74M

Put Options Held

1.84M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.93B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stevard, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stevard, LLC with notifications on news.

Account